Original research

Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis

Matthew D Rutter 1,2, Matthew Brookes 3,4, Thomas J Lee 5, Peter Rogers 6, Linda Sharp 2

ABSTRACT

Objective The COVID-19 pandemic has had a major global impact on endoscopic services. This reduced capacity, along with public reluctance to undergo endoscopy during the pandemic, might result in excess mortality from delayed cancer diagnosis. Using the UK’s National Endoscopy Database (NED), we performed the first national analysis of the impact of the pandemic on endoscopy services and endoscopic cancer diagnosis.

Design We developed a NED COVID-19 module incorporating procedure-level data on all endoscopic procedures. Three periods were designated: pre-COVID (6 January 2020 to 15 March), transition (16–22 March) and COVID-impacted (23 March–31 May). National, regional and procedure-specific analyses were performed. The average weekly number of cancers, proportion of missing cancers and cancer detection rates were calculated.

Results A weekly average of 35478 endoscopy procedures were performed in the pre-COVID period. Activity in the COVID-impacted period reduced to 12% of pre-COVID levels; at its low point, activity was only 5%, recovering to 20% of pre-COVID activity by study end. Although more selective vetting significantly increased the per-procedure cancer detection rate (pre-COVID 1.91%; COVID-impacted 6.61%; p<0.001), the weekly number of cancers detected decreased by 58%. The proportion of missing cancers ranged from 19% (pancreatitis) to 72% (colorectal).

Conclusion This national analysis demonstrates the remarkable impact that the pandemic has had on endoscopic services, which has resulted in a substantial and concerning reduction in cancer detection. Major, urgent efforts are required to restore endoscopy capacity to prevent an impending cancer healthcare crisis.

INTRODUCTION

COVID-19 is an infectious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus which was initially detected in Wuhan, China, in November 2019. Since the detection of this novel virus there, it has been declared a global pandemic by the WHO in March 2020.1 As of 9 June 2020, it has infected over 7.25 million people worldwide, and caused more than 410 000 deaths.2 The pandemic has represented a unique challenge to all clinical services, including endoscopy, with its severity, virulence and unprecedented scale.3

The clinical characteristics of COVID-19 include a febrile and inflammatory biphasic illness with associated respiratory tract inflammation.4 5 GI manifestations are associated but seem less prevalent than in prior SARS or Middle East respiratory syndrome.6 Evidence has established that COVID-19 is mainly spread via droplets and contact.3 5,9 Additionally, there are now data supporting airborne spread during aerosol-generating procedures, which include endoscopy.3 9 This has implications for healthcare professionals (HCPs) performing or assisting with
these procedures: indeed, around 3.8% of the initial cohort of confirmed cases of COVID-19-associated mortality were seen in HCPs in China. More recent UK data (up to 20 April 2020) have shown that rates of death in COVID-19 in HCPs were not higher than the general population; 10.2 deaths per 100 000 men (43 deaths) and 4.8 deaths per 100 000 woman (63 deaths). Further challenges to the provision of endoscopy in the current pandemic include asymptomatic carriers spreading the virus to close contacts, and the findings that many of these asymptomatic cases had detectable viral loads similar to those with prominent symptomatology.

In response to these worldwide issues, most gastroenterology societies in jurisdictions affected by the pandemic, including the European Society for Gastrointestinal Endoscopy, the American Society for Gastrointestinal Endoscopy and the Asian-Pacific Society of Digestive Endoscopy, issued guidance to cease non-urgent endoscopic activity, with the British Society of Gastroenterology (BSG) and Joint Advisory Group for Gastrointestinal Endoscopy (JAG) advice published on 23 March 2020. This guidance included the postponement of non-emergency cases, bowel cancer screening and surveillance which have impacted on the cancer diagnostic pathway. Although this guidance has complicated fast-track referral cases can be assessed on a case-by-case basis, it is likely that these have been significantly delayed. The wider implications from guidance on the provision of endoscopy services are covered elsewhere in more detail.

The impact of this reduction in endoscopic diagnostic service provision is currently ill defined. In other European countries, COVID-19 has reduced overall cancer diagnostics and led to reductions in cancer diagnoses by between 26% (non-skin cancer) and up to 60% (skin cancer). We are yet to see what impact this pandemic and the associated reduction in GI endoscopy has had on the diagnosis of GI cancers, but there is increasing concern that delay in treatment of even 3 months will have a significant impact of cancer survival. As the pandemic transmission rate reduces in the UK, there has been further advice on recommencing endoscopy services, but this guidance may be slow to implement in light of issues around provision of personal protective equipment (PPE), other measures aimed to reduce potential COVID-19 transmission within endoscopy centres and patient reluctance to attend for procedures.

Currently, 411 of 520 (79%) of UK Endoscopy units, including both the state and private sector, provide uploaded data to the National Endoscopy Database (NED), which holds data from over 2.5 million endoscopic procedures. This resource can provide a unique insight how national guidance generated to prevent COVID-19 transmission may have changed service provision. Additionally, this database allows us to demonstrate the reduction in cancer diagnosis rates in the upper and lower GI tract in the COVID-19 compared with the prepandemic era.

The aim of this paper was to use NED to examine in detail the historical changes in endoscopy service provision and cancer diagnosis in the immediate pre-COVID-19 era and during the early phase of the pandemic.

**METHODOLOGY**

NED is an established national database which automatically captures near-real-time data from each endoscopy procedure that an endoscopy service performs. The development of NED has previously been published. Endoscopic retrograde cholangiopancreatography (ERCP) upload is not currently mandatory. As this study was service evaluation, ethical approval was not required.

For this current research, the NED IT team developed a dedicated COVID-19 module (Microsoft.Net, Microsoft SQL Server, Microsoft Analysis Services OLAP; Microsoft Corporation) incorporating procedure-level data on all endoscopic procedures, including date of the procedure, procedure urgency, indication and cancer diagnosis, patient age and sex, endoscopist and endoscopy service, segmented in weekly intervals. We downloaded data for a 21-week period starting 6 January 2020 and ending 31 May 2020.

For analysis purposes, we designated three periods: a stable pre-COVID period, reflecting normal UK endoscopy workload (10 weeks from 6 January–15 March), a transition week (from 16 March–22 March, when UK endoscopic practice was highly variable) and a COVID-impacted period (10 weeks from 23 March–31 May). The average number of procedures in each period was computed, and the percentage reduction in activity calculated for the transition and COVID-impacted periods compared with the pre-COVID period. This was done for all procedures in the UK, the four nations and English regions. It was repeated by procedure type (colonoscopy, flexible sigmoidoscopy, oesophagogastroduodenoscopy (OGD), ERCP) and for Bowel Cancer Screening Programme (BCSP) procedures and other (non-BCSP) procedures.

χ² tests were used to compare the age, sex and urgency (emergency, urgent, surveillance, routine, not specified) distribution of the procedures conducted in the pre-COVID and COVID-impacted periods, overall and by procedure type. The average weekly number of cancers detected at endoscopy, and cancer detection rate (with 95% CIs), was computed by period and the rates compared using z-tests. To derive the number of ‘missing cancers’ in the COVID-impacted period, we calculated the number of cancers that would have been expected in the COVID-impacted period (had the pre-COVID activity and cancer detection rates applied) and subtracted the number of cancers detected in the COVID-impacted period. This was also expressed as a percentage of the cancers detected in the pre-COVID period (% of cancers missing). Finally, we computed the number of procedures needed to detect one cancer in each period.

**RESULTS**

**Endoscopy workload**

On average, 35 478 endoscopy procedures were performed per week (by 3007 endoscopists; mean 12 procedures per endoscopist) in the pre-COVID period. In the transition week, this fell by one-third, to 23 827. In the COVID-impacted period, only 12% of the pre-COVID volume of procedures were conducted (average 4315 per week, performed by 922 endoscopists; mean 4 procedures per endoscopist; table 1 and figure 1). At its low point, by the end of March, fewer than 1800 procedures per week were being conducted: 5% of pre-COVID activity. This continued for the following 2 weeks, after which a modest week-on-week rise began, such that by the last 2 weeks of May, on average 6974 procedures were being undertaken per week undertaken: a fourfold increase from the end of March but still only 20% of pre-COVID activity.

Endoscopy training reduced from a mean of 1930 training procedures per week in the pre-COVID period (performed by 380 trainees; mean of 5 procedures per trainee), to a mean of 133 training procedures per week in the COVID-impacted period (performed by 46 trainees; mean of 3 procedures per trainee): a 93% reduction.
When procedure types were considered, the average reduction in weekly activity compared with pre-COVID was substantial for low colonoscopy (90%), flexible sigmoidoscopy (91%) and OGD (86%). In contrast, the reduction was only 44% for ERCP procedures (table 1). For BCSP procedures, the decline in BCSP flexible sigmoidoscopies commenced at the start of March, while the volume of BCSP colonoscopies was maintained until mid-March (figure 2). In the COVID-impacted period, the reduction in weekly procedure volume, compared with pre-COVID, was 97% for BCSP colonoscopies and 99% for BCSP flexible sigmoidoscopies.

Regional variation
Analysis by UK nation showed no substantial differences (online supplementary table 1): in the COVID-impacted period, the reduction in activity compared with the pre-COVID period across nations ranged from 84% in Wales to 88% in England, and within England from 85% (South West and West Midlands) to 91% (East England and Greater London).

Case mix
The case mix of patients seen in the transition and COVID-impacted period was significantly different from the pre-COVID case mix (table 2). For all procedures combined, the proportion of older patients (aged 70 and above) was higher in COVID-impacted (39%) period, than pre-COVID (29%; p<0.001) and men comprised a higher proportion of patients (53% vs 49%; p<0.001). These patterns were most pronounced for flexible sigmoidoscopies.

**Table 1** Weekly number of procedures by time period and change over time, overall and by procedure type

| Procedure type | Time period* | Pre-COVID | COVID impacted |
|----------------|--------------|-----------|----------------|
| All            |              | 35 478    | 4312           |
| % reduction in activity compared with pre-COVID | 87.8         |
| Colonoscopy    |              | 12 646    | 1300           |
| % reduction in activity compared with pre-COVID | 89.7         |
| Flexible sigmoidoscopy |            | 7335      | 632            |
| % reduction in activity compared with pre-COVID | 91.4         |
| OGD            |              | 14 985    | 2091           |
| % reduction in activity compared with pre-COVID | 86.0         |
| ERCP           |              | 513       | 289            |
| % reduction in activity compared with pre-COVID | 43.7         |

*Pre-COVID 16 January 2020–15 March 2020; COVID-impacted 23 March 2020–31 May 2020

ERCP, endoscopic retrograde cholangiopancreatography; OGD, oesophagogastroduodenoscopy.
COVID-19

Figure 2 Number of Bowel Cancer Screening Programme (BCSP) and non-BCSP procedures per week, by procedure type.

Cancers
The number of cancers detected at endoscopy decreased from an average of 677 per week in the pre-COVID period to 283 per week in the COVID-impacted period (table 3) meaning that 394 cancers per week were ‘missing’ during the COVID-impacted period; this represents 58% of all cases that would have been expected to be detected in this time. The proportion of ‘missing cancers’ ranged from 19% for pancreatobiliary cancers to 72% for colorectal cancers.

Reflecting the change in case mix, the overall per-procedure cancer detection rate rose significantly (pre-COVID 1.91 per 100 procedures; COVID-impacted 6.61 per 100 procedures; difference=4.70 per 100 procedures (95% CI 4.46 to 4.94), p<0.001; table 3). There was a significant increase in the per-procedure detection rate for colorectal, oesophageal, gastric and pancreatobiliary cancers. Overall, the number of procedures conducted per cancer decreased, from 52 in the pre-COVID to 15 in the COVID-impacted period. This was evident for all groups (table 3).

DISCUSSION
We have used a national database, populated by automated real-time capture of endoscopy reports and holding over 2.5 million endoscopic records, to achieve an accurate perspective of the impact of the COVID-19 pandemic on endoscopic workload and endoscopic cancer diagnosis. Whereas earlier modelling work has been performed, we believe that this is the first such national analysis.

Our study shows the profound effect that the pandemic has had on endoscopy services in the UK: by the end of March, endoscopic activity was running at 5% of pre-COVID activity. This substantial reduction has been seen across all UK regions and endoscopic procedures (although ERCP activity, being mostly emergencies, has been relatively well preserved). The initial reduction in endoscopic activity occurred in the week commencing 16 March 2020, when several hospitals, particularly in London, were experiencing a surge in COVID-19 admissions and hospitals across the UK were restructuring services to deal with the pandemic. There was also increasing awareness that upper GI endoscopies were aerosol-generating procedures and concern about faecal shedding of SARS-CoV-2. The demand for national advice was addressed with the publication of the BSG/JAG guidance for endoscopy services on 23 March,15 which advised that all non-emergency endoscopic procedures should stop immediately, after which our NED analysis demonstrates that almost all non-emergency endoscopy activity ceased across the UK. In addition to this national guidance, endoscopy services faced several other logistical challenges, including inadequate sigmoidoscopy and OGD. For ERCP, there was a different pattern of change in the age distribution of patients; greater proportions were aged 50–59 and 60–69, and a smaller proportion was aged 70 and over in the COVID impacted, compared with the pre-COVID period (p=0.013).

Compared with the pre-COVID period, in the COVID-impacted period, the proportions of emergency procedures and those considered urgent increased while routine and surveillance procedures decreased (pre-COVID: emergency 2%, urgent 35%; COVID impacted: emergency 6%, urgency 60%; p<0.001; table 2). This increase in urgency procedures was seen for all procedure types and was most pronounced for OGD (rise from 28% to 57%) and least pronounced for ERCP (52% to 69%).
availability of appropriate PPE, staff redeployment to pandemic-related activities and some endoscopy units being repurposed for COVID-related work.

Our study shows the dramatic and concerning effect that the reduction in endoscopy has had on cancer diagnosis—58% of expected cancers have not been detected, ranging from a 19%

| Procedure type | Time period* | Pre-COVID | COVID impacted |
|----------------|--------------|-----------|----------------|
|                | N            | %         | N              | %              |
| Overall        |              |           |                |                |
| Age group      |              |           |                |                |
| <40            | 49 443       | 13.9      | 4607           | 10.7           |
| 40–49          | 40 110       | 11.3      | 3945           | 9.1            |
| 50–59          | 88 631       | 25.0      | 7680           | 17.8           |
| 60–69          | 72 467       | 20.4      | 10 209         | 23.7           |
| 70+            | 104 099      | 29.3      | 16 675         | 38.7           |
| Sex            |              |           |                |                |
| Females        | 179 244      | 51.0      | 20 093         | 47.3           |
| Males          | 172 051      | 49.0      | 22 416         | 52.7           |
| Urgency        |              |           |                |                |
| Emergency      | 5478         | 1.5       | 2508           | 5.8            |
| Urgent         | 123 651      | 34.9      | 25 598         | 59.4           |
| Surveillance   | 19 226       | 5.4       | 649            | 1.5            |
| Routine        | 168 339      | 47.4      | 9367           | 21.7           |
| Not specified  | 38 084       | 10.7      | 4998           | 11.6           |
| Colonoscopy    |              |           |                |                |
| Age group      |              |           |                |                |
| <40            | 16 259       | 12.9      | 1247           | 9.6            |
| 40–49          | 15 160       | 12.0      | 1222           | 9.4            |
| 50–59          | 26 074       | 20.6      | 2619           | 20.1           |
| 60–69          | 32 495       | 25.7      | 3875           | 29.8           |
| 70+            | 36 463       | 28.8      | 4035           | 31.0           |
| Sex            |              |           |                |                |
| Females        | 62 223       | 49.8      | 6373           | 49.8           |
| Males          | 62 840       | 50.2      | 6422           | 50.2           |
| Flexible sigmoidoscopy | | | | |
| Age group      |              |           |                |                |
| <40            | 10 270       | 14.0      | 1085           | 17.2           |
| 40–49          | 5998         | 8.2       | 582            | 9.2            |
| 50–59          | 33 589       | 45.8      | 974            | 15.4           |
| 60–69          | 8297         | 11.3      | 1225           | 19.4           |
| 70+            | 15 188       | 20.7      | 2456           | 38.8           |
| Sex            |              |           |                |                |
| Females        | 35 994       | 49.5      | 2975           | 47.5           |
| Males          | 36 780       | 50.5      | 3286           | 52.5           |
| ERCP           |              |           |                |                |
| Age group      |              |           |                |                |
| <40            | 369          | 7.2       | 239            | 8.3            |
| 40–49          | 322          | 6.3       | 178            | 6.2            |
| 50–59          | 616          | 12.0      | 396            | 13.7           |
| 60–69          | 954          | 18.6      | 568            | 19.7           |
| 70+            | 2865         | 55.9      | 1508           | 52.2           |
| Sex            |              |           |                |                |
| Females        | 2759         | 54.5      | 1429           | 50.3           |
| Males          | 2299         | 45.5      | 1414           | 49.7           |

*Pre-COVID 6 January 2020–15 March 2020; COVID-19 impacted 23 March 2020–31 May 2020.
†From χ² test of association.
‡Implausible ages recorded for 33 procedures; sex not recorded for 4095 procedures; urgency not recorded for 1 procedure.
ERCP, endoscopic retrograde cholangiopancreatography; OGD, oesophagastroduodenoscopy.
reduction for pancreatobiliary cancers to a 72% reduction for colorectal cancer.

Our data are consistent with the impact on cancer diagnosis identified in a recent report, which showed a reduction in the diagnosis of all cancers across the Netherlands, similar assumptions have been raised by Cancer Research UK. This delay is of great concern: a recent modelling study indicated that even modest delays in surgery for cancer of 3–6 months might incur significant impact on survival, particularly for stage 2 or 3 cancers.

Our study shows that whereas the overall number of cancers being detected has dropped significantly, the detection rate of endoscopic tests for cancer has increased significantly during the COVID-19 pandemic. This is due to the selective nature of endoscopic procedures being performed during the pandemic, focusing on patients whose symptoms and baseline tests indicate the highest risk of cancer. Strategies have included senior clinician vetting of all endoscopic referrals (compared with much open-access endoscopic workload pre-pandemic) and using other investigations such as faecal immunochemical test (FIT) testing and cross-sectional imaging to stratify risk and identify

| Procedure type | Time period* | Pre-COVID | COVID impacted | Change in cancer detection rate |
|----------------|--------------|-----------|----------------|---------------------------------|
| All cancers    |              | 677       | 283            |                                 |
| Cancer detection rate (per 100 procedures) | 1.91 (1.86–1.95) | 6.61 (6.38–6.85) | 4.70 (4.46–4.94), p<0.001 |
| Missing cancers in period | 3939 | 3928 | 51 |
| % of cancers ‘missing’ | 58.2% | 71.7% | 37.1% |
| Number of procedures per cancer | 52 | 17 |
| Colorectal cancers (colonoscopy and flexible sigmoidoscopy) | 394 | 112 |
| Cancer detection rate (per 100 procedures) | 1.97 (1.91–2.03) | 5.77 (5.44–6.10) | 3.80 (3.46–4.13), p<0.001 |
| Missing cancers in period | 2828 |
| % of cancers missing | 71.7% |
| Number of procedures per cancer | 51 | 17 |
| Oesophageal cancers (OGD) | 205 | 129 |
| Cancer detection rate (per 100 procedures) | 1.37 (1.31–1.43) | 6.16 (5.84–6.49) | 4.80 (4.47–5.13), p<0.001 |
| Missing cancers in period | 759 |
| % of cancers missing | 37.1% |
| Number of procedures per cancer† | 56 | 13 |
| Gastric cancers (OGD) | 61 | 29 |
| Cancer detection rate (per 100 procedures) | 0.41 (0.38–0.44) | 1.40 (1.24–1.56) | 0.99 (0.83–1.15), p<0.001 |
| Missing cancers in period | 320 |
| % of cancers missing | 52.3% |
| Number of procedures per cancer† | 56 | 13 |
| Pancreatobiliary cancers (ERCP) | 17 | 14 |
| Cancer detection rate (per 100 procedures) | 3.36 (2.77–3.74) | 5.21 (4.35–6.07) | 1.95 (0.97–2.94), p<0.001 |
| Missing cancers in period | 32 |
| % of cancers missing | 19.2% |
| Number of procedures per cancer | 31 | 19 |

*Difference in numbers of cancers detected in COVID-impacted period compared with number expected had the same number of weekly procedures and cancer detection rate applied as in pre-COVID period; % of cancers missed is this difference expressed as percentage of number of cancers expected.
†Pre-COVID 16 January 2020–15 March 2020; COVID-19 impacted 23 March 2020–31 May 2020.
‡Number of oesophagogastroduodenoscopy (OGD) procedures per cancer (oesophageal and gastric cancers combined).
ERCP, endoscopic retrograde cholangiopancreatography.

Whether such mechanisms persist and/or prove useful in the later phases of recovery remains to be seen.

Our data reveal a small increase in endoscopic workload since the end of March, recovering to 20% of pre-COVID activity by the end of our analysis. While this recovery is small, in comparison with pre-COVID levels, it nevertheless represents a fourfold increase from its nadir, driven by increasing concerns about the detrimental impact of delayed cancer diagnosis and confidence that hospitals were coping with the COVID-19 workload, admissions for which were beginning to decline.

We believe the slow speed of recovery of endoscopic activity has been multifactorial. First, many of the original reasons for reduced activity (staff redeployment, illness and shielding/self-isolation, repurposing of some units, PPE shortages) have remained. Second, endoscopy services have had to restructure, introducing social distancing, enforced downtime and additional cleaning between procedures and PPE donning and doffing, all of which substantially reduce patient throughput. Finally, but importantly, we believe the national public message to ‘stay at home’, along with daily news about hospitals being inundated with COVID-19 cases, many of whom were dying, resulted in...
the public being reluctant both to present to general practitioners (whose services were also significantly stretched) and to attend hospital appointment, both from fear of catching COVID-19 in hospital and from a desire not to overburden hospital services.

Limitations of this paper include NED currently only covering 79% of UK endoscopy units (lower for ERCP, which is not mandatory at present)—however, this is felt to be broadly representative of the entire UK endoscopy practice. It is possible that during the pandemic, some endoscopy services have utilised endoscopy units that are not currently uploading to NED, resulting in an under-reporting of current endoscopic activity; however, it is also possible that some non-NED uploading units are now using facilities (eg, independent sector endoscopy units) that are uploading to NED, correcting previous under-reported—we feel, therefore, that these changes are unlikely to have had a significant impact on UK endoscopy reporting.

Another limitation is that cancer diagnosis in NED relates to the endoscopic diagnosis, rather than histologically confirmed cancers; thus, there is potential for false-negative cases (eg, a cancer focus in a resected polyp) and false-positive cases (where the endoscopist misinterpreted benign pathology for a cancer). However, as these limitations are common to all NED reports irrespective of timeframe, we do not think they will have introduced any bias to the diagnosis of cancer in this study. Finally, it is possible that some of the cancers that would normally be detected by endoscopy have been diagnosed by alternative investigation; however, while it is likely that some cancers have been identified by, for example, cross-sectional imaging, in most cases a tissue diagnosis would still be required and therefore these cases would still undergo endoscopy.

CONCLUSION

Using the UK’s NED, we have performed the first national analysis of the impact of the COVID-19 pandemic on endoscopy services and endoscopic cancer diagnosis. Our study confirms the remarkable impact the pandemic has had on endoscopic workload, which has resulted in a substantial and concerning reduction in cancer detection. Major, urgent efforts are required to restore endoscopy capacity.

Twitter Matthew Brookes @GastroMJB

Acknowledgements The authors would like to acknowledge the NED committee, JAG and all 411 UK endoscopy sites that upload data to the National Endoscopy Database.

Contributors All authors conceived, wrote and reviewed the paper. PR provided IT input. LS analysed the data. MDR was responsible for overall content as guarantor.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data were derived from the National Endoscopy Database. Data relevant to the study are included in the article or uploaded as supplementary information.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID IDs Matthew D Rutter http://orcid.org/0000-0001-9507-0295

Linda Sharp http://orcid.org/0000-0001-9515-1722

REFERENCES

1 Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207.

2 Johns Hopkins University. Coronavirus COVID-19 global cases for the center for systems science and engineering (CSSE). Available: https://www.arcgis.com/apps/opsdashboard/index.html#/bda759470s450/299424675/48e9ee16

3 Lui RN, Wong SH, Sánchez-Luna SA, et al. Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol 2020;35:749–59.

4 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

5 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. doi:10.1001/jama.2020.1585. [Epub ahead of print: 07 Feb 2020].

6 Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol 2020;35:744–8.

7 To KK-W, Tsang OT-Y, Chik-Yan YP, C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020. doi:10.1093/cid/ciaa149. [Epub ahead of print: 12 Feb 2020].

8 Zhang J, Wang S, Yue X. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol 2020;92:680–2.

9 Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential Fecal-Oral transmission. Gastroenterology. 2020;158:1518–9.

10 Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. doi:10.1001/jama.2020.2648. [Epub ahead of print: 24 Feb 2020].

11 Coronavirus (COVID-19) related deaths by occupation, England and Wales: deaths registered up to and including 20 April 2020. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesofdeath/bulletins/coronavirus-relateddeathsbyoccupationenglandandwales/deathregistrationsuportedandincluding20april2020

12 Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970–1.

13 Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020. doi:10.1001/jama.2020.2565. [Epub ahead of print: 21 Feb 2020].

14 Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177–9.

15 Endoscopy activity and COVID-19: BSG and JAG guidance. Available: https://www.bsg.org.uk/covid-19-advice/endoscopy-activity-and-covid-19-bsg-and-jag-guidance/

16 Dimmohamed AG, Visser Q, Verhoeven RHA, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol 2020;21:750–1.

17 Suid A, Jones ME, Broglio J, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020. doi:10.1016/j.annonc.2020.05.009. [Epub ahead of print: 19 May 2020].

18 BSG Guidance on recommencing GI endoscopy in the deceleration and early recovery phases of the COVID-19 pandemic. Available: https://www.bsg.org.uk/covid-19-advice/bsg-guidance-on-recommencing-gi-endoscopy-in-the-deceleration-early-recovery-phases-of-the-covid-19-pandemic

19 Scally G, Jacobson B, Abassi K. The UK’s public health response to covid-19. BMJ 2020;369:m1932.

20 Lee TJ, Siau K, Emaily S, et al. Development of a national automated endoscopy database: the United Kingdom national endoscopy database (NED). United European Gastroenterol J 2019;7:798–806.

21 Over 2 million people waiting for cancer screening, tests and treatments, 2020. Available: https://scienceblog.cancerresearchuk.org/2020/06/01/impact-of-coronavirus-on-cancer-services-revealed-over-2-million-people-waiting-for-screening-tests-and-treatments/

22 Covid-19: NHS outlines services to be prioritised to restart in next six weeks, 2020. Available: https://doi.org/10.1136/bmj.m1793